Amended Current Report Filing (8-k/a)
August 04 2022 - 8:12AM
Edgar (US Regulatory)
0000827871
false
0000827871
2022-07-28
2022-07-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report (Date of
earliest event reported): July 28, 2022
Eagle Pharmaceuticals, Inc.
(Exact name of registrant
as specified in its charter)
Delaware |
001-36306 |
20-8179278 |
(State
or other jurisdiction |
(Commission File Number) |
(IRS Employer Identification No.) |
of
incorporation) |
|
|
50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ |
|
07677 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (201) 326-5300
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which
registered |
Common Stock (par value $0.001 per share) |
|
EGRX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
This Amendment
No. 1 on Form 8-K/A, or the Amended 8-K, is being filed as an amendment to the Current Report on Form 8-K filed by Eagle Pharmaceuticals,
Inc., or the Company, with the Securities and Exchange Commission on August 1, 2022, or the Original 8-K. The purpose of this Amended
8-K is to disclose the Company’s decision regarding how frequently it will conduct future shareholder non-binding advisory votes
to approve the compensation of the Company’s named executive officers. No other changes are being made to the Original 8-K.
Item 5.07 Submission of Matters to a Vote of Security Holders.
As reported in the Original 8-K, at the Company’s Annual Meeting
of Shareholders held on July 28, 2022, a majority of the Company’s shareholders that voted on the matter indicated a preference
to hold, on a non-binding advisory basis, the Company’s future non-binding advisory votes on executive compensation, or say on pay
votes, every year. After taking into consideration the foregoing voting results and the Board of Directors’ prior recommendation
in favor of an annual say on pay votes as set forth in the Company’s proxy statement for the Company’s 2022 Annual Meeting
of Shareholders, and consistent with the shareholder voting results, the Board has determined that the say on pay vote will be conducted
once every year, until the next shareholder vote on say on pay frequency.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: August 4, 2022 |
EAGLE PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Scott Tarriff |
|
|
Scott Tarriff |
|
|
Chief Executive Officer |
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024